In 2024, the Company shifted its focus from developing therapeutics for neuronal excitability disorders to immune-mediated diseases. In connection with this shift, the Company ceased its operations in the U.K. and separated from seven U.K. employees in 2024. The costs associated with this headcount reduction were fully recognized and all of the related payments were made by December 31, 2024. A summary of the restructuring costs recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2024 were as follows (in thousands):


	Year Ended December 31, 2024
	ROU Asset Impairment		Severance and Benefit Costs		Stock-based Compensation		Total Restructuring Cost Recorded
Research and development expenses	$	—	$	1,778	$	944	$	2,722
General and administrative expenses		—		475		161		636
Total restructuring costs	$	—	$	2,253	$	1,105	$	3,358